Table 4.
Meta-analysis for the outcomes of blood lipids, blood pressure, and adverse effects.
| Outcomes | No. of trial | WMD/RR | 95% CI | p | p; I2 | Effect model |
|---|---|---|---|---|---|---|
| TC | 22 | -0.04 | -0.06 to -0.03 | < 0.001 | 0.039; 37.8% | FE |
| TG | 22 | -0.04 | -0.05 to -0.03 | < 0.001 | 0.019; 42.5% | FE |
| HDL-C | 22 | 0.01 | -0.00 to 0.02 | 0.143 | 0.025; 40.9% | FE |
| LDL-C | 22 | -0.26 | -0.54 to 0.03 | 0.078 | < 0.001; 95.6% | RE |
| SBP | 15 | -2.01 | -3.17 to -0.86 | 0.001 | 0.410; 3.8% | FE |
| DBP | 15 | -0.82 | -2.23 to 0.60 | 0.257 | 0.010; 52.1% | RE |
| Adverse effects | 14 | 0.97 | 0.62 to 1.52 | 0.905 | 0.533; 0.0% | FE |
WMD, weighted mean difference; RR, relative risk; CI, confidence interval; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; FE, fixed-effects model; RE, random-effects model.